Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Praxis Precision Medicines Announced Topline Results For Its Phase 2 Study Of Relutrigine In SCN2A And SCN8A Developmental And Epileptic Encephalopathy Patients, Showing Placebo-adjusted Monthly Motor Seizure Reduction Of 46% During Double-blind Period

Author: Benzinga Newsdesk | September 03, 2024 07:32am

Posted In: PRAX